Home > Oncology > SABCS 2021 > Phase 1–3 Trials > Trastuzumab deruxtecan outperforms trastuzumab emtansine

Trastuzumab deruxtecan outperforms trastuzumab emtansine

Presented By
Dr Sara Hurvitz, University of California, CA, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
SABCS 2021
Trial
Phase 3, DESTINY-Breast03
Both trastuzumab deruxtecan and trastuzumab emtansine have shown to improve progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer. In a head-to-head comparison, trastuzumab deruxtecan proved to outperform trastuzumab emtansine. Trastuzumab deruxtecan is a HER2-targeting, antibody-drug conjugate for the treatment of previously treated patients with advanced HER2-positive metastatic breast cancer, as was demonstrated by the DESTINY-Breast01 study (NCT03248492) [1]. Before, the EMILIA trial (NCT00829166) showed trastuzumab emtansine to be beneficial in this population [2]. In the phase 3 DESTINY-Breast03 (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on